Primary Immune Deficiency (PID) — Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)
Citation(s)
A Multi-centre, Open-label, Cross-over Study to Compare the Pharmacokinetics, Safety and Tolerability of Ig NextGen 10% With Intragam P in Patients With Primary Immune Deficiency (PID)